FloridaTaper

Category: Symptoms

Physical, cognitive, and psychological symptoms in taper and post-taper states.

  • Histamine Intolerance During Benzodiazepine Withdrawal: Is a Low-Histamine Diet Worth Trying?

    Histamine Intolerance During Benzodiazepine Withdrawal: Is a Low-Histamine Diet Worth Trying?

    Is a low-histamine diet worth trying during benzodiazepine withdrawal?

    For some people, yes, as a short experiment with an end date written on the calendar before it starts. A low-histamine diet can tell you within a few weeks whether the food on your plate is adding to your symptoms. What it cannot do is heal the reason the reactions began.

    If Tuesday’s leftover chili now does what Monday’s did not, you have probably met the phrase “histamine intolerance” in a forum, along with long food lists and a promise that eating around them will fix things. So, how much of that promise holds up?

    Histamine intolerance is a framework, and not everyone accepts it.

    Histamine is a chemical your own body makes and releases, and it is also in food, especially aged or fermented food. The framework says that some people take in more histamine than they can break down, and that the excess produces symptoms that look like an allergy without being one. The usual explanation is that a gut enzyme, diamine oxidase (DAO), is not keeping up.

    That framework is contested, which is worth knowing before you reorganize your kitchen around it. The evidence for it is thin, and the food lists that come with it disagree about tomatoes, spinach, and whether a banana is a threat. Yet, the practical question survives: does eating this way change how you feel?

    Professor C. Heather Ashton noticed the same reactions decades ago. In Chapter III of the Ashton Manual, under protracted gastrointestinal symptoms, she wrote that some people in withdrawal “develop apparent intolerance to certain foods” while tests for true food allergy “are nearly always negative.”

    Why does histamine come up in withdrawal at all?

    Nobody knows for certain, and the honest explanations we have are all hedged. One idea is that mast cells, the immune cells that store and release histamine, become easier to trigger while the nervous system is running hot. Another is that the autonomic nervous system, which the Ashton Manual says may be overactive in withdrawal, amplifies a small histamine release.

    While the mechanism is uncertain, the timeline is not, and in Dr. Leeds’ view the timeline matters more: these reactions tend to ease as withdrawal does. Of course, none of this makes the reactions imaginary, and the allergy-like symptoms of benzodiazepine-induced neurological dysfunction (BIND) are part of the picture.

    What does a histamine-type picture look like from the inside?

    It looks like new reactions to particular foods within an hour or two of eating, rather than at random. Aged cheese, cured and smoked meat, sauerkraut and kimchi, kombucha, vinegar, canned or day-old fish, and alcohol are the usual offenders. Leftovers are a tell, because on this account histamine builds as food ages.

    The symptoms tend to travel in a group: flushing, headache, a stuffy nose, a racing heart, itching or hives, stomach cramping, and a sudden low or anxious mood. A pattern patients often describe: months past the last dose, the small glass of wine that never used to bother them now brings on a hot face and a racing heart, and they have quietly stopped eating out. If the symptoms have no relationship to meals, the diet is unlikely to tell you much.

    Some of these symptoms are not withdrawal and need to be checked.

    Before any diet trial, a few patterns should send you to a doctor rather than to a food list. Hives with swelling of the lips, tongue, or throat, or with wheezing or trouble breathing, are not histamine intolerance and need emergency care the first time they happen. The same is true for flushing with chest pain or fainting: call 911, and do not let a forum talk you out of it.

    Other red flags are quieter. Flushing with persistent diarrhea and weight loss, fever, blood in the stool, a reaction to one food every time no matter how fresh, or symptoms that began before the taper all deserve their own workup, because a true allergy, a gut infection, and a thyroid problem can each imitate this picture. Mast cell activation syndrome (MCAS) also comes up, and that is a diagnosis a physician makes with specific criteria, not a label from a checklist.

    What does the diet actually involve?

    While the exclusion list looks long, the principle is short: eat fresh and eat simply for a few weeks. Meat and fish are cooked and eaten the same day, fruit leans to apples, pears, and blueberries rather than citrus, most vegetables are fine, though most lists set aside tomatoes, spinach, eggplant, and avocado for the trial weeks, and grains, eggs, and fresh dairy suit many. Aged, fermented, cured, canned, and leftover foods come off the menu, and so does alcohol.

    Sticking to it is harder than it sounds. Every meal has to be made fresh, eating out becomes a guessing game about how long the fish sat in the kitchen, and social meals get awkward fast.

    The structured trial is the whole point.

    A low-histamine diet run for two to four weeks, with a symptom diary and a planned reintroduction at the end, is a diagnostic experiment. The same diet run indefinitely because it seemed to help a little is an exclusion diet with no exit, and the Ashton Manual says plainly that it is “usually inadvisable to stick to a strict exclusion diet.”

    The diary does the work. Each day, rate the two or three symptoms you care most about on a simple scale, note what you ate, and anything else that might explain a bad day, such as poor sleep or a taper step. In fact, memory is a poor instrument here, because a person who has just spent three weeks avoiding cheese wants the avoidance to have mattered.

    At the end of the window, bring foods back one at a time, two or three days apart, with the diary still running. A clear reaction to one food is specific information about you. Or, if nothing much changed during the strict weeks, you have also learned something: histamine is not the main driver, the diet can end, and the search moves on.

    Why not just stay on it, if it helps?

    Because the reason it helps is expected to fade. The reactions belong to a nervous system unwinding from physical dependence on a drug taken as prescribed, and physical dependence is not addiction. Dependence is an adaptation, its slow reversal is what you are living through, and the food reactions are part of that reversal rather than a separate illness. The Ashton Manual’s table of protracted symptoms lists gastrointestinal symptoms as “gradually improving but may last a year and occasionally several years,” and Professor Ashton’s advice was a normal balanced diet while they abate.

    There are costs on the other side too. A long, narrow diet raises nutritional questions worth reviewing with your doctor or a dietitian. And, in Dr. Leeds’ experience, long avoidance can breed its own problem: food becomes frightening, the safe list keeps shrinking, and reintroduction gets harder the longer it is put off.

    What about antihistamines and the other medicines people mention?

    That is an individual conversation with your prescriber. There are medicines that act on histamine receptors and medicines meant to steady mast cells, and some patients find one helpful while others feel nothing or feel worse. Which, if any, is reasonable for you depends on your other medicines and where you are in the taper, and some antihistamines add to the sedation of a benzodiazepine.

    So, the medicine question is yours and your prescriber’s to settle. Enzyme capsules are sold on the theory that they replace what the gut is short of, and whether they do anything for a given person is unknown, so they too are a question for your doctor rather than a forum. Whatever you decide, a benzodiazepine is never stopped abruptly to see whether the reactions go away. The 2020 label update from the U.S. United States Food and Drug Administration (FDA) spells out why: stopping abruptly or reducing the dose too quickly “can result in withdrawal reactions, including seizures, which can be life-threatening.”

    The reactions are real, and they are usually temporary.

    A rain barrel is a fair picture of the framework, though not a perfect one. Histamine flows in from food and your own cells, a drain at the bottom carries it away, and symptoms appear when the water rises over a line near the rim. Withdrawal seems to narrow the drain and lower the line at once, so a normal day’s inflow overflows.

    Where the picture fails is that the barrel is not fixed. As the nervous system settles, the drain widens again, so a diet that mattered in month three may not matter in month twelve. The one instruction the picture supports is to lower the inflow for a few weeks, watch the level, and see how much the barrel handles.

    While it is tempting to build an identity around a diet that once helped, the better use of it is as a three-week question with a written answer. Run the trial, keep the diary, bring the foods back, and let the list of what you avoid get shorter as the months pass. Fortunately, for most people in withdrawal, it does.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • When a Neurologist Orders an MS Workup for a Patient With BIND: What the Differential Should Include

    When a Neurologist Orders an MS Workup for a Patient With BIND: What the Differential Should Include

    A patient with paresthesias, tremor, fatigue, cognitive dysfunction, and sensory disturbances arriving at a neurology clinic will often leave with an order for a multiple sclerosis (MS) workup. The reasoning is straightforward: the symptom list triggers the MS differential, and a prudent neurologist wants to exclude a treatable and progressive neurological disease before settling on less specific explanations. For patients with benzodiazepine-induced neurological dysfunction (BIND), this is usually the right clinical instinct to follow, since MS can occur in patients who happen to have a benzodiazepine history, and its exclusion is genuinely useful. What often goes wrong is what happens after the MS workup returns negative, and what the rest of the differential should have included alongside MS from the beginning.

    Why the MS Differential Gets Triggered

    Several features of BIND present as neurological symptoms that a neurologist examining the patient for the first time could reasonably read as MS.

    Paresthesias and dysesthesias are the most common trigger. Tingling, numbness, burning sensations, and altered tactile perception can appear in various distributions. MS classically produces patchy, asymmetric sensory changes corresponding to demyelinating lesions, while BIND produces more diffuse, bilateral sensory symptoms, but the distinction is not always clean at presentation. Both conditions also produce substantial fatigue that is out of proportion to activity.

    Cognitive dysfunction overlaps as well. MS can produce slowed processing speed, attention difficulties, and executive dysfunction, and BIND produces similar cognitive features, so a neurologist evaluating the cognitive complaint alone may consider MS reasonably. Visual symptoms overlap too. Blurred vision, floaters, and altered visual perception occur in both. Optic neuritis is a defining MS event; BIND does not produce optic neuritis but can produce visual symptoms that prompt an evaluation for it.

    Tremor is common in BIND and can also appear in MS. Ataxia and coordination difficulties are less common in BIND than in MS but can occur, and both conditions can affect balance and gait. Autonomic features overlap as well: MS can involve urinary urgency, bowel changes, and sexual dysfunction, while BIND frequently involves broader autonomic dysfunction.

    One caution belongs here, because overlap is not sameness. Sudden loss of vision in one eye, new weakness or numbness confined to one side of the body, trouble speaking, or a first seizure are not symptoms to wait out as withdrawal; they need emergency care the same day, so call emergency services if they appear.

    What the MS Workup Typically Shows

    The standard MS workup includes magnetic resonance imaging (MRI) of the brain and cervical spine with and without contrast, evaluation of cerebrospinal fluid (CSF) for oligoclonal bands and the immunoglobulin G (IgG) index, and often evoked potentials. Supportive laboratory evaluation typically includes vitamin B12, thyroid function, and other mimics.

    There is no BIND-specific imaging or spinal fluid literature to point to, so what follows is clinical experience rather than a published series. In Dr. Leeds’ experience, and in what patients in the BIND community consistently report, the structural workup comes back normal.

    MRI is usually unremarkable. There are no demyelinating lesions in the periventricular, juxtacortical, infratentorial, or spinal cord distributions that MS diagnostic criteria require, and brain parenchyma appears normal or shows age-appropriate changes.

    CSF is usually negative for oligoclonal bands not present in serum, the IgG index is not elevated, and CSF cell counts and protein are unremarkable. Evoked potentials, when performed, tend to be normal or non-specific.

    The workup essentially excludes MS.

    What Should Be Part of the Differential Alongside MS

    A neurologist evaluating the same symptom picture should ideally consider several additional diagnoses from the start, not only after MS has been excluded.

    BIND itself belongs on the list. In a patient with long-term benzodiazepine exposure and a recent taper or discontinuation, BIND is a specific diagnostic candidate supported by an established clinical framework. The clinical features, which are time-locked to benzodiazepine changes, accompanied by autonomic and sensory hypersensitivity, and fluctuating in the waves-and-windows pattern, are recognizable.

    Vitamin B12 deficiency produces peripheral neuropathy, paresthesias, ataxia, and cognitive symptoms. Serum B12 with methylmalonic acid and homocysteine for borderline values is appropriate. Severely low vitamin D has been associated with neurologic symptoms and is cheap to exclude. Both hyperthyroidism and hypothyroidism can produce cognitive, autonomic, and motor symptoms, and thyroid-stimulating hormone (TSH) is the standard screen.

    In regions where Lyme disease is common, or with a compatible exposure history, Lyme serology is worth including, with the understanding that the tests have limits and a result needs interpretation rather than a glance. Celiac disease can produce peripheral neuropathy, ataxia, and cognitive symptoms, sometimes as the presenting features. Tissue transglutaminase immunoglobulin A (IgA) with total IgA is the screening combination.

    Other demyelinating conditions, including neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG) antibody disease, have their own antibody tests, as does autoimmune autonomic neuropathy, and a neurologist will know when the picture calls for them.

    Medication effects deserve a full review. Not only benzodiazepines but also fluoroquinolones, metronidazole, chemotherapy agents, statins in some patients, and other medications can produce neurological symptom pictures. The full medication list belongs in every workup of this kind.

    Functional neurological disorder (FND) has specific rule-in criteria and should not be a diagnosis of exclusion after a normal workup. The clinician should test for FND signs specifically (Hoover’s sign, tremor entrainment, tubular visual fields) and apply the label only when they are present, not when everything else is negative.

    Where the Diagnostic Error Usually Happens

    The typical failure mode in this clinical scenario is a neurologist who completes an MS workup, finds it negative, and concludes “no neurological disease.” The symptoms are then attributed to anxiety, functional etiology, or somatization, and the patient is referred back to psychiatry or discharged from neurology follow-up.

    This is an error for several reasons.

    MS-negative does not mean neurological-disease-negative. The MS differential is narrow; many non-MS neurological conditions produce similar symptom pictures and require different tests to identify.

    BIND is a neurological condition, not a psychiatric one, even though it lacks the structural imaging findings of classical neurology. It is also a condition of physical dependence, which is not addiction: the nervous system adapted to a prescribed medication and is now destabilized by its reduction or absence, and nothing about that requires a psychiatric or addiction explanation. A neurologist who does not consider pharmacologically-driven neurological dysfunction as part of the differential is working with an incomplete framework.

    Defaulting to FND without rule-in criteria produces the same misdiagnosis pattern seen elsewhere on this site, where BIND is relabeled as an unrelated condition, and the same collision plays out when BIND is mistaken for fibromyalgia. FND exists as a positive diagnosis; it is not “everything else has been ruled out.”

    What the Patient Can Ask For

    For a patient headed into an MS workup in the context of a benzodiazepine history, several requests shift the evaluation toward a more useful outcome.

    Ask that the benzodiazepine history and taper timeline be explicitly documented in the neurology note. A workup pursued in the context of acknowledged benzodiazepine exposure produces more useful subsequent discussion than a workup that implicitly treats the patient as free of relevant medication history.

    Request that BIND be considered as one possibility alongside MS. Providing background on the BIND framework in advance can orient a neurologist unfamiliar with it.

    Ask that the workup include B12, methylmalonic acid, homocysteine, vitamin D, TSH, celiac serology, and Lyme serology (where exposure is plausible) alongside the MRI and CSF. These are low-cost additions that broaden the differential meaningfully.

    If the MS workup is negative, request that the neurologist document specifically which diagnoses are being considered next rather than defaulting to “non-neurological” or “functional.” A differential explicitly including BIND, mimic conditions, and specific alternative neurological diagnoses is more useful for future clinical care than a negative conclusion.

    Ask for follow-up rather than discharge if BIND is being considered. BIND patients benefit from neurology follow-up even when the structural workup is negative; autonomic and sensory symptoms may require specific management, and the label of a recognized syndrome in the chart aids subsequent care.

    What a Good Neurology Note Looks Like

    For a BIND patient whose MS workup returned negative, a well-constructed neurology note reads something like this: structural MS workup is negative; the clinical picture is compatible with benzodiazepine-induced neurological dysfunction; alternative mimics (B12 deficiency, thyroid dysfunction, Lyme disease, celiac disease) have been evaluated and are not contributory; ongoing management will focus on the benzodiazepine taper and recovery with follow-up at regular intervals.

    Compared to a note that says “no evidence of neurological disease; recommend psychiatric follow-up,” the useful version accomplishes several things: it acknowledges the syndrome by name, documents the negative workup in context, aligns future clinicians with the relevant framework, and preserves the clinical relationship for ongoing care.

    The point of an MS workup in a BIND patient is to exclude MS. The workup accomplishes that efficiently when pursued appropriately. What matters equally is that the broader differential is considered from the start, so that a negative MS workup narrows the question rather than ending it.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • Does Long-Term Klonopin Cause Emotional Blunting? What Patients Describe but Doctors Miss

    Does Long-Term Klonopin Cause Emotional Blunting? What Patients Describe but Doctors Miss

    Does long-term Klonopin cause emotional blunting?

    For many people, yes. Clonazepam, sold as Klonopin, is a long-acting benzodiazepine, and years of daily use commonly narrow the range of what a person can feel. The Ashton Manual, in Chapter I under the heading “Depression, emotional blunting”, calls this “emotional anaesthesia”, the inability to feel pleasure or pain, and describes it as a common complaint of long-term benzodiazepine users.

    You will rarely find it in your chart. Patients notice it years into treatment, if they notice it at all, and most file it under getting older or being stably medicated.

    So, two questions follow. Why does a change this large go unrecorded for years, and what happens to it when the drug is slowly withdrawn?

    You still feel, just less of everything.

    Patients reach for the same picture: a volume knob turned down on the whole board at once rather than on a single channel. Grief is quieter, and so are joy, irritation, and desire. A child’s graduation or a parent’s funeral registers as the event it is, and the feeling arrives at half strength.

    What sets this apart from depression is that you know what is missing. A person in a deep depression often cannot picture ever having felt otherwise, while a blunted patient remembers full emotional range clearly and can describe the gap.

    Daily life usually continues. Yet, patients describe watching their own lives with less investment, or, in a phrase many of them use, sleepwalking through them. Another phrase that comes up again and again is “I can’t cry”, from someone standing dry-eyed in situations that should bring tears and aware of it.

    Why does nobody mention it at the visit?

    Because you do not lead with it. You come in with anxiety, sleep, or a physical symptom, and “I feel less than I used to” is not a complaint most people think to make. It tends to be volunteered only when someone asks directly, or when a taper makes the contrast available.

    The prescriber’s side has its own blind spot. A patient who is less reactive, less tearful, and less easily rattled can look, from across the desk, like one whose anxiety is finally well controlled. In medicine, we are good at asking about sadness and poor at asking about range, so the loss goes unrecorded and the prescription is renewed.

    Unfortunately, the people around you often notice first. The Ashton Manual observes that former long-term users often bitterly regret their lack of emotional response to their children and partners during the years on the drug, and the toll on families deserves its own telling.

    Is it depression, or is it the drug?

    Often it is read as depression, and the reading is understandable. Less pleasure, less engagement, and no tears are three things a mood questionnaire asks about. A patient who endorses them is usually offered an antidepressant, most often a selective serotonin reuptake inhibitor, or SSRI, and the benzodiazepine that may be causing the flatness goes unexamined.

    In Dr. Leeds’ experience, that second medicine rarely restores what the first one took, and many patients report feeling flatter still with both on board. When the antidepressant produces no lift, that is sometimes read as a partial response calling for a higher dose or a third drug, which is the shape of a prescribing cascade: a drug’s effect treated as a new disease.

    Yet, the two can coexist, and the Manual is careful on the point. It notes that long-term users are often depressed, that the depression may first appear during prolonged use, and that benzodiazepines can both cause and aggravate it. Klonopin’s own label lists depression among the adverse reactions in its panic disorder trials and warns that antiepileptic drugs, clonazepam included, can increase the risk of suicidal thoughts or behavior.

    So, flatness on long-term clonazepam deserves a look at the clonazepam before a diagnosis is added, without assuming the drug explains everything. If you are having thoughts of harming yourself, that comes before any taper question. Call or text 988, the Suicide and Crisis Lifeline in the United States, or go to the nearest emergency department, and let the sorting-out come afterward.

    Why would a calming drug flatten feeling?

    Nobody knows in detail, and it is better to say so. The Ashton Manual, in the same passage, says the blunting is “probably related to the inhibitory effect of benzodiazepines on activity in emotional centres in the brain”, and one way to read that is that the inhibition which quiets anxiety cannot leave feeling alone. Going back to the volume knob, there is no separate channel for dread.

    While this is not a perfect analogy, it fits what patients report: short courses rarely do this, and years at ordinary prescribed doses commonly do. Ask whether the dial has moved, then, because you are the only person who can hear the difference.

    Does a slow taper bring feeling back?

    Usually, and slowly. The Ashton Manual does not track this symptom on its own, but Chapter III says that in most people withdrawal symptoms disappear within a few months and that a steady decline almost invariably continues after withdrawal. Blunting, in Dr. Leeds’ experience, follows that pattern: most people regain range, some regain it completely, and some carry a degree of flatness for a long time afterward.

    The timeline is months rather than weeks, and feeling often returns in patches before it settles. A person who has not cried in a decade may find tears arriving over a song midway through a taper, and grief that was muted years ago can surface with its original weight. Most patients call this welcome even when it is uncomfortable, because it means the range is returning.

    Not everyone gets all of it back. A minority describe blunting that persists into protracted withdrawal, in some cases for years, though even then it tends to improve slowly rather than not at all. Whether that reflects a lasting change from prolonged exposure, a separate condition the drug had masked, or one face of benzodiazepine-induced neurological dysfunction, or BIND, is an open question.

    Why does it have to be a taper rather than a stop?

    Years of daily clonazepam produce physical dependence, meaning the nervous system has adjusted itself around the drug and now needs it to hold steady. Physical dependence is not addiction. It was created by a prescription taken as directed, not by urges or misuse, which is why the way out is medical and gradual rather than a matter of willpower.

    Klonopin’s label, which carries the Food and Drug Administration’s 2020 boxed warning for all benzodiazepines, states that abrupt discontinuation or rapid dosage reduction after continued use may precipitate acute withdrawal reactions, which can be life-threatening, and that a gradual taper reduces that risk. It also acknowledges a protracted withdrawal syndrome lasting weeks to more than a year.

    So, do not stop clonazepam on your own or skip doses to test whether feeling returns. A seizure is one possible answer, and a seizure after a missed or reduced dose is an emergency: call 911.

    How slow is slow enough is worked out between you and your prescriber. The Ashton Manual’s schedules and the Maudsley Deprescribing Guidelines both describe small reductions held long enough for the nervous system to catch up, with the Maudsley approach making each step smaller as the dose gets lower. The pace is set by how you tolerate each step, never by a calendar.

    What should you ask for at your next visit?

    Start with one question the standard mood screen does not ask: “Do I feel emotions with the same intensity as before I started this medication?” Put it to yourself first, then to your prescriber in those words, because it opens a conversation that “How is your anxiety?” never will.

    Then look at the timing together. Blunting that began in the first year on the drug and has held steady since points toward the medication. Flatness that arrived recently in someone stable on clonazepam for a decade deserves a wider look: a new medicine, a recent loss, a medical problem such as thyroid disease, or a depression of its own.

    Some signs mean this needs checking now rather than watching: sudden onset, hopelessness, thoughts of death, new confusion, or marked changes in weight or sleep. Those are not taper questions, and they should not wait for the next visit.

    Fortunately, the trade-off itself is plain. If clonazepam is still doing real work for a hard anxiety condition and the flatness is mild, continuing may be a reasonable choice, and it is yours to make. If the flatness troubles you most and the reason the drug was started has passed, a slow taper is the conversation worth having, decided with your prescriber and never started alone.

    Keep a record while you decide, and during any taper. A few lines a week on what you felt and how strongly gives the next visit something better than recall, and it lets you see the dial move in a direction too slow to notice day to day.

    Naming the quiet out loud, to yourself and then to your doctor, is usually the first thing that changes. And, for most people, the range does come back, at a pace set by the nervous system rather than by anyone’s wishes. Somewhere in the months of a careful taper, something ordinary will land with its full weight, and you will know it when it does.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • Does Long-Term Clorazepate Use Set Off a Prescribing Cascade of New Diagnoses and New Drugs?

    Does Long-Term Clorazepate Use Set Off a Prescribing Cascade of New Diagnoses and New Drugs?

    What is a prescribing cascade?

    A prescribing cascade is what happens when a side effect of one medication is mistaken for a new illness and treated with a second medication, whose side effects are mistaken for a third illness and treated again. Nobody plans one, and each step looks reasonable at the time.

    Long-term benzodiazepine use is a reliable place for a cascade to begin, because the drug’s later effects look so much like other diseases. Clorazepate, sold as Tranxene, produces a slow and quiet version of the pattern. So, how does one prescription turn into four, and how do you get the chain to stop?

    Why is clorazepate so hard to see through?

    Clorazepate is a prodrug: the tablet you swallow is not the active drug. Once swallowed, it is quickly converted, by a reaction the label calls decarboxylation, into nordiazepam, also known as desmethyldiazepam.

    The Ashton Manual, in Chapter I, Table 1, lists the half-life of clorazepate’s active metabolite at 36 to 200 hours, and the drug’s own label gives nordiazepam an apparent half-life of about 40 to 50 hours and says it shows moderate accumulation with repeated dosing. As a result, levels build for weeks after daily dosing starts and fall just as slowly when a dose is lowered.

    An analogy that might help is a bathtub with a partly open drain. Open the tap a little and the water rises for a long time before it settles, and close it a little and it drops just as slowly. While this is not a perfect analogy, it explains why you can feel worse three weeks after a change you have already stopped thinking about, and why a reduction should be judged weeks later, not the next morning.

    Your anxiety got worse on a steady dose. Is that the drug?

    Many people on a long-term benzodiazepine find that anxiety creeps back after years on the same dose, sometimes with tremor, tingling, a pounding heart, or panic that never happened before. The Ashton Manual’s Chapter I section on tolerance describes exactly this: as the brain adapts, withdrawal symptoms can emerge even while the drug is still being taken.

    Physical dependence is not addiction. A person who took clorazepate as prescribed for ten years has a body that adapted to it, a medical condition caused by the prescription, and that adaptation produces these symptoms.

    Unfortunately, the usual response is more treatment: a higher benzodiazepine dose, a selective serotonin reuptake inhibitor (SSRI), or an antipsychotic. While any of these may bring a few weeks of relief, the tolerance pattern tends to return at the new level, and nobody asked whether the anxiety was the drug’s own effect.

    You are tired and flat, and someone called it depression.

    Long-acting benzodiazepine metabolites cause daytime drowsiness and slowed thinking, and on clorazepate that sedation is steady rather than in waves. Too often, it gets relabeled as fatigue or depression and treated with an antidepressant, occasionally a stimulant, while the benzodiazepine’s share goes unexamined.

    People who have taken a benzodiazepine for years also describe a narrowed emotional range, which Professor C. Heather Ashton called “emotional anaesthesia” in Chapter I of the Ashton Manual, and a doctor can read that flatness as anxiety under control. Emotional blunting on Klonopin follows the same shape, and the same misreading.

    Low mood still deserves to be taken seriously. If you are having thoughts of harming yourself, call or text 988, the Suicide and Crisis Lifeline, or go to an emergency department, and let the drug question wait.

    Your memory is slipping, and the word dementia came up.

    The Ashton Manual notes that complete tolerance to the effects on memory and cognition does not seem to occur, and that in older people benzodiazepines can produce confusion, unsteadiness, and what Chapter I calls “pseudodementia.” In a younger person the same fog gets worked up as attention deficit hyperactivity disorder (ADHD), with a stimulant to follow, and in an older person as early dementia.

    Fortunately, this impairment is often at least partly reversible once the drug is slowly reduced, which makes either label costly. A workup that never asks what you have been taking for a decade can miss the one reversible cause on the list.

    You cannot sleep, so a second sedative was added.

    Benzodiazepines taken during the day can disturb sleep at night, especially once tolerance to the sedative effect has set in, and the complaint that follows is insomnia. The common answer is a second sedating drug on top of the first, whether quetiapine, trazodone, or zolpidem, and now you take two sedatives with overlapping risks.

    If the sleeping pill helps for a while and then stops, that is the same tolerance pattern arriving on the second drug. Before a third is added, the older prescription is the one to ask about.

    Falls, an irritable streak, and a racing heart each got their own workup.

    Oversedation is more marked in older people and, as the Ashton Manual puts it, may contribute to falls and fractures. When a fall is treated as a bone problem and nobody reviews the medication list, the drug that caused the fall stays on the list.

    Rarely, a patient becomes irritable, impulsive, or agitated on a benzodiazepine, which the clorazepate label calls a paradoxical or disinhibitory reaction and which the Ashton Manual says is most frequent in older people and children. Read as new bipolar disorder or a personality problem, the change earns a mood stabilizer or an antipsychotic, and the cause is never named.

    Gut and autonomic symptoms do the same. Constipation, reflux, palpitations, temperature swings, and dizziness on standing can appear during long-term use, and each can generate its own specialist, testing, and drug. Dysautonomia after long-term benzodiazepine use deserves the drug question before the testing begins.

    None of this means every new symptom is the benzodiazepine. Chest pain, a seizure, fainting, sudden loss of vision or hearing, new weakness on one side, or a fall with a blow to the head are emergencies that need 911 or an emergency department, whatever list you are on.

    Why does this keep happening to careful doctors?

    Of course, prescribing cascades come from how medical care is arranged, far more than from careless doctors. Visits are short, specialists work in silos, and the fastest path out of a short visit is a new prescription.

    Electronic records list recent additions at the top and old renewals at the bottom, and a prescription refilled every ninety days for ten years stops looking like a decision and starts looking like furniture. And, when a patient suggests the old prescription as the cause, the reply is often reassurance rather than a review. Yet, this is not a plea against doctors, most of whom were never taught about tolerance and work in a system that pays for additions, not subtractions.

    How do you interrupt a cascade?

    The first move is a question, asked before any new prescription: could this be the drug? For any new symptom on a long-term benzodiazepine, the medication list, with start dates and past dose changes, is the first thing to check.

    The second move is to consider a reduction before an addition. If the new symptom might be tolerance, sedation, or disinhibition, a slow, small dose reduction made with your prescriber tells you more than a new drug would, because the symptom either eases or does not. Both the Ashton Manual and the Maudsley Deprescribing Guidelines describe such symptoms being mistaken for the original condition or a new illness, and this step follows from that, though neither states it as a rule.

    A reduction is never the same as stopping. Since the 2020 United States Food and Drug Administration (FDA) label update, clorazepate carries a boxed warning that abrupt discontinuation or rapid dosage reduction can precipitate acute withdrawal reactions that can be life-threatening, and the label names seizures among them and calls for a gradual taper. The pace is between you and your doctor, with you directing the speed as tolerated.

    The third move is a standing review of every chronic medication at a visit set aside for it. How often that would catch a cascade is not a number this article can give you, only a pattern that doctors who taper these drugs see often, and experience varies.

    What is different when the drug is clorazepate?

    Clorazepate’s wrinkle is that nordiazepam builds and clears so slowly that its sedation and fog develop over weeks and outlast any single dose, which makes them hard to connect to the tablet. The effect of lowering it may not be fully visible for two to three weeks, so reductions are usually made less often than with a short-acting benzodiazepine, and each is judged with patience.

    Dr. Leeds’ view, shared by the sources this site cites, is that the reduction is small, slow, and patient directed. On clorazepate that patience matters twice over, because the drug’s own timetable is slow.

    A composite pattern: a patient in their sixties on clorazepate for years is seen for tiredness and started on an antidepressant, then for poor sleep and given a sleeping pill, then for confusion and sent for a memory workup. Nobody on that chain had a reason to pull the first prescription forward. The patient’s own question, at the fourth visit, finally did.

    What happens when you ask the question yourself?

    You are allowed to ask whether an old prescription could be causing a new symptom, and to ask again if the first answer is reassurance. Bring the whole list, with dates, and ask your doctor to look at it with you before the next addition.

    Still, time is on your side once the drug question is in play. Sedation, fog, and flatness from a long-acting benzodiazepine tend to lift as the level comes down over the weeks the drug takes to leave, and whatever remains is a shorter, more honest list to bring back to your doctor.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • Seroquel for Sleep: When an Antipsychotic Becomes the Problem

    Seroquel for Sleep: When an Antipsychotic Becomes the Problem

    Why would a doctor give you an antipsychotic to help you sleep?

    Seroquel, or quetiapine, is an antipsychotic. Its label from the United States Food and Drug Administration (FDA) lists schizophrenia and bipolar disorder, and the extended-release label adds a role as an add-on to an antidepressant in major depression. Insomnia appears nowhere on either list.

    Yet, if you are partway through a benzodiazepine taper and sleeping badly, someone has probably already offered you a small bedtime dose as something mild for sleep. At low doses quetiapine mostly blocks the histamine H1 receptor, the same receptor that older allergy pills block, and blocking histamine makes people drowsy.

    It is also not a controlled substance, and the Ashton Manual, in Chapter II, warns against z-drugs for withdrawal insomnia because they act like benzodiazepines. So, the patient who would have declined an antipsychotic accepts a sleep aid, and nobody at the visit uses the first word. What does it cost to borrow sleep from one?

    What does a small dose of quetiapine do to the rest of you?

    More than the phrase “something mild” suggests. The label warns that quetiapine can raise blood sugar, disturb blood lipids, and add weight, and it advises checking all three during treatment, which often does not happen when the drug was prescribed only for sleep.

    The label also warns that quetiapine can drop your blood pressure when you stand, with dizziness and in some people fainting, which for a person who gets up at night is a fall waiting to happen. And, it carries an anticholinergic load, bringing dry mouth, trouble emptying the bladder, and constipation severe enough that the label warns of bowel obstruction.

    Akathisia, an inner restlessness that makes it hard to sit still, can appear even at sleep doses in clinical experience, and it is regularly mistaken for worsening anxiety, which prompts a higher dose that makes it worse.

    Quetiapine also lengthens the QT interval, a measure on an electrocardiogram of how long the heart takes to recharge between beats. So, the label says to avoid combining it with other drugs that do the same, including certain heart-rhythm drugs and some antibiotics.

    Some of these are not withdrawal and should not be waited out. A pounding or irregular heartbeat, a high fever with stiff muscles, severe belly pain with vomiting, or extreme thirst and urination each need a doctor promptly.

    Fainting, chest pain, a seizure, or thoughts of harming yourself are emergencies, so call 911 or go to the emergency department. Call or text 988 if the thoughts are of self-harm, a risk the label carries as a boxed warning for young people treated for depression.

    Can you become dependent on a sleep dose of quetiapine?

    Yes. The label says that acute withdrawal symptoms, insomnia, nausea, and vomiting among them, have been described after abrupt cessation of antipsychotics including Seroquel, and its longer list adds headache, diarrhea, dizziness, and irritability. Its instruction is four words long: gradual withdrawal is advised.

    Professor Ashton wrote in Chapter III of the Ashton Manual that withdrawal reactions are a normal response to stopping many long-used drugs, antipsychotics among them. Nobody uses the vocabulary of misuse for a sleep pill, yet the same people may quietly decide that you must need it.

    Physical dependence is not addiction. Your body adjusted to a drug that arrived every night for months, and it objects when the drug is gone, a medical condition caused by the prescription and nothing more.

    How long does it last? While the label says the symptoms usually resolve within about a week, that figure comes from short trials at treatment doses, and none of the sources this site cites can say whether some people have a longer course. In clinical experience it varies.

    Why is the rebound insomnia not your old insomnia coming back?

    Because the timing and the shape give it away. Insomnia heads the label’s list of discontinuation effects, and patients who stop quetiapine suddenly often describe several nights of almost no sleep, vivid dreams when sleep finally comes, and a wired, agitated feeling by day. The original complaint was rarely that dramatic.

    One likely explanation is that histamine was held down every night, the brain compensated, and when the drug leaves, the histamine system overshoots for a while, though that is a mechanism nobody has measured well. The Ashton Manual describes a similar overshoot of dreaming sleep after benzodiazepine withdrawal in the Chapter III section on insomnia, nightmares, and sleep disturbance. Two rebounds at once is a bad night.

    The reflexive conclusion is that the medication is needed after all, and the tablets go back in the drawer by the bed. In Dr. Leeds’ view that conclusion is usually wrong, because rebound is withdrawal, and a drug restarted every time the rebound appears never gets tapered at all.

    How does one taper turn into two?

    Dr. Leeds sees the pattern often enough to describe it as one story: a patient months into a careful taper mentions poor sleep, a small bedtime dose of quetiapine is added, and the sleep improves for a few weeks. A year later the patient is off the benzodiazepine and asking how to stop the sleep pill, a second withdrawal created by the management of the first.

    While this is not a perfect analogy, adding quetiapine to cover taper insomnia is a bit like taking out a second loan to make the payments on the first. The payments stop hurting for a while. Yet, you now owe two lenders, and the second one collects on its own schedule, with terms you were never shown.

    So, ask to see the repayment terms before you sign, which in plain language means the exit plan. Unfortunately, the second loan is rarely explained as a loan.

    Insomnia during a benzodiazepine taper is common enough to have its own article on this site. A side effect of one drug is a reason to reopen the conversation about that drug and its pace, not a reason to add a second drug on top of it.

    Professor Ashton said as much in the Chapter III section on extra medication: sedating relatives of the major tranquilizers, sometimes prescribed during withdrawal, can cause movement disorders and are no substitute for a benzodiazepine.

    The benzodiazepine comes off first, and the two never move together.

    That is Dr. Leeds’ view, and the reasoning is simple: two withdrawals at once multiply the sleepless nights and make it impossible to tell which drug is causing what.

    Finish the benzodiazepine taper, give the nervous system months to settle, and then take up the quetiapine with the prescriber. Neither drug ever comes off abruptly, whatever order you and your doctor settle on.

    There is no one-size-fits-all order. While a person who took the antipsychotic for years before the benzodiazepine has a different history to weigh with their doctor, the rule that survives every history is that the two do not move together, even when that means carrying a drug you never wanted for another year.

    How slowly should quetiapine come down?

    Slowly, in steps that shrink as the dose falls. The Maudsley Deprescribing Guidelines set out the principle behind that shape, called hyperbolic tapering: a drug’s effect on its receptors does not fall in a straight line with the dose, so the reductions near the end need to be the smallest.

    The Maudsley volume in print covers antidepressants, benzodiazepines, gabapentinoids, and z-drugs, and a companion volume on antipsychotics has been announced but has not arrived, so for now there is no Maudsley quetiapine schedule to quote, whatever a forum post claims. That leaves the label’s “gradual withdrawal is advised” and clinical experience, which varies, and neither belongs on a website as a milligram schedule.

    The smallest tablet on the label is 25 mg, so near the end tablets get split, a compounded liquid is one option for the last stretch, and how far down to go is a matter for you and your prescriber, not a search engine.

    When a reduction brings a rebound flare, holding at the current dose until the nights settle keeps the ground you gained. And, sleep work in parallel gives the brain something to lean on other than a receptor.

    Cognitive behavioral therapy for insomnia (CBT-I) is one route, and the Ashton Manual’s plain measures for withdrawal insomnia, no caffeine or alcohol near bedtime and exercise by day, are another. Some patients find one enough and some use both.

    What should you ask before the first tablet?

    Fortunately, the questions are simple, asking them is not an act of defiance, and they are the ones you would put to any lender before signing.

    Why this drug for sleep, when its own label never mentions insomnia? What is the plan for coming off of it, and when will that plan be revisited? What will be checked along the way? What are the alternatives, including a slower benzodiazepine taper and no additional medication at all?

    You are allowed to decline, and to change your mind later without losing your doctor’s goodwill. Informed consent means the risks come first, the exit plan is part of the first conversation, and the decision remains yours as the months go by.

    A person who takes quetiapine with open eyes and a written exit plan is in a different position from one who was handed it as something mild. If you are already in the second position, there is no cause for alarm, only a plan to write down at your next visit.

    The drug then comes off the same way it should have gone on, slowly and on purpose, with your doctor as a partner. Nobody described that part at the first visit, which is one more reason to put it on the agenda for the next one.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • Tolerance Withdrawal, or Why Benzo Symptoms Can Begin Before the Taper Does

    Tolerance Withdrawal, or Why Benzo Symptoms Can Begin Before the Taper Does

    Can you be in benzodiazepine withdrawal while taking every dose on time?

    Yes, and it is easy for a prescriber to miss. A person who has taken a benzodiazepine for years, at the same dose, can slide into withdrawal without missing a pill. Chapter I of the Ashton Manual, in its section on tolerance, describes withdrawal symptoms emerging even in the continued presence of the drug, and patient communities call the state tolerance withdrawal.

    Withdrawal is supposed to happen when a drug is taken away, and here the drug is still being taken. Yet, the symptoms are real, they are new, and they are usually answered with more of the medication that is producing them. So, what does tolerance withdrawal look like from the inside, why does an office visit miss it, and what changes once it has a name?

    Tolerance is the brain adjusting to a drug that is always there.

    Benzodiazepines work by strengthening the brain’s main calming signal, a chemical called gamma-aminobutyric acid, or GABA. When that signal is boosted every day for months or years, the brain adjusts by turning its own calming machinery down. In plain terms, the brakes weaken, and the dose that once produced calm now holds the line at best.

    That adjustment is physical dependence, and physical dependence is not addiction. Nobody here has misused anything, and a brain that has adapted to a prescribed medication has a medical condition, treated with a gradual taper rather than a program.

    The Ashton Manual puts the consequence plainly. The original dose has progressively less effect, anxiety often increases over the years despite continuous use, and panic attacks and agoraphobia may appear for the first time after years of taking the drug.

    The first clue is that the symptoms are new.

    Tolerance withdrawal is routinely mistaken for the original condition getting worse, so ask whether these symptoms were ever part of it. A person who started a benzodiazepine for panic attacks a decade ago and now has numbness around the mouth, tingling in the hands and feet, muscle twitching, an inner tremor, ringing in the ears, and a stomach that rejects ordinary food had none of that at the start. While anxiety is a plausible explanation for some of it, it is an implausible explanation for all of it at once.

    Sensory and autonomic features are the ones most often reported as new: light too bright, sound too loud, a startle at ordinary noises, swings in temperature, and a heart that races without a reason. A common pattern in clinic is a person told, visit after visit, that their anxiety is progressing, when the anxiety they came in with was a fear of flying and what they have now is a fear of the supermarket lights.

    The second clue is that the symptoms keep time with the clock.

    On shorter-acting benzodiazepines such as alprazolam (Xanax) and lorazepam (Ativan), the blood level peaks and dips between doses, and Chapter II of the Ashton Manual, in its section on switching to a long-acting benzodiazepine, notes that many people experience a mini-withdrawal between each dose. In clinical experience, mornings can be the low point for the same reason, with agitation or a pounding heart that lifts an hour or two after the first dose.

    The third clue is that a higher dose stops holding.

    Dose increases stop holding: relief often lasts only a few weeks, and the symptoms return at the new dose. While this is not a perfect comparison, it is a little like a furnace running on one setting in a house that is slowly growing drafty: turning the dial up warms the rooms for a while, and then the drafts catch up. Look at the drafts, meaning the adaptation, rather than at the dial.

    Some of these symptoms are not withdrawal until a doctor has checked.

    Tolerance withdrawal is a pattern, and patterns can be imitated by a thyroid or rhythm problem, a vitamin deficiency, a nerve problem, or a medication started in the same window. Fortunately, most of what tolerance withdrawal produces is miserable rather than dangerous, and a few ordinary tests usually rule out the imitators.

    Some symptoms should never be filed under withdrawal on your own. Chest pain or pressure, a racing heart with fainting, a first-ever seizure, a sudden loss of vision or hearing, weakness on one side of the body, new confusion, or a severe headache unlike any before need to be checked the same day, and if any of them is happening now, call 911 or go to the nearest emergency department. If you are having thoughts of harming yourself, call or text 988, the Suicide and Crisis Lifeline, now.

    Why does a short visit miss it?

    Unfortunately, the standard office visit is built to miss it. A patient on a long-term benzodiazepine says they feel more anxious, the visit has fifteen minutes in it, and the question that fits is whether the anxiety is worse, not whether it has changed shape. The pen is moving toward a higher dose before the tingling and the ringing ears have been mentioned.

    There is an honest difficulty underneath the hurried one. Tolerance withdrawal and a genuine worsening of an anxiety disorder overlap, and we cannot measure a brain’s adaptation to a drug in an office. So, the distinction has to be made from the history, and the history is something only you can supply.

    A higher dose or a second drug is the usual reflex, and the wrong one.

    In medicine, we are trained to answer a worsening symptom by adding to the treatment, and the training serves well right up until the treatment is the cause. The brain adapts to a higher dose the way it adapted to the old one, and the ladder gains a rung. A second drug instead, most often a selective serotonin reuptake inhibitor, or SSRI, or a sedating medication for sleep, leaves the adaptation untouched and adds a medication that can carry its own dependence and withdrawal.

    In fact, the reflex comes from the wish to relieve suffering, and in this one situation it points the wrong way. Dr. Leeds’ view is that recognizing tolerance changes the conversation from how much more to add to how to unwind what is already there, safely and slowly. Nothing in that conversation involves stopping suddenly, since the 2020 United States Food and Drug Administration (FDA) benzodiazepine label update warns that stopping abruptly, or reducing the dose too quickly, can bring on withdrawal reactions, including seizures, which can be life-threatening.

    What does tolerance withdrawal change about the taper?

    It changes the starting line. A person who is already in withdrawal experiences the first reductions on top of a baseline that already contains withdrawal, which is why the first stretch of a taper is often planned very slowly, sometimes after a hold.

    Some patients report feeling steadier during the first weeks of a well-planned taper, which may reflect the end of dose increases and irregular timing. Clinicians who taper benzodiazepines see this often enough to mention it, but it is clinical experience, it varies, and no one should be told to expect it.

    Timing can matter as much as amount. Spreading doses evenly across the day softens the dips that drive interdose symptoms, as the article on why a hold can feel worse than a cut explains.

    For shorter-acting drugs, the Ashton Manual’s approach is a crossover taper to a longer-acting benzodiazepine, usually diazepam (Valium), chosen for its slow, smooth fall in blood level. The Maudsley Deprescribing Guidelines treat that switch as one tool among several rather than a universal step, and which path fits is a decision for you and your doctor.

    What should you bring to the visit?

    A dated timeline of symptoms is the most useful thing you can bring. Write down when each symptom first appeared, what the dose was at the time, and whether it comes and goes with the clock. Handwritten is fine, and a page of dates does more than an hour of description.

    Bring a dose history as well: which drug, how much, how often, and every increase over the years with a rough date. Saying that these symptoms are new since the medication and follow the dosing schedule asks a different question than saying your anxiety is worse, and most doctors will engage with it.

    Of course, a doctor may hesitate. You may raise it anyway, and ask whether a gradual taper, planned together, is worth discussing. The doctor must work out the pace with you, and one who has seen the timeline usually has an easier time saying yes.

    Naming it early changes what the taper is doing from the first day.

    In clinical experience, tolerance withdrawal is not rare, and it is often the first chapter of a story that ends, years later, in protracted withdrawal. That is an observation from practice, which varies, and not a rule.

    A person who recognizes it early begins the taper knowing what the symptoms are, and that knowledge takes much of the fear out of the process. If dependence, tolerance, and toxicity are still tangled, the article on the difference between the three sorts them out.

    The brain that adapted to the drug can adapt again in the other direction, on its own slow schedule, which no one can hurry. What you can do this week is start the timeline, and bring it to your next visit.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.